Modality
Peptide
MOA
VEGFi
Target
RET
Pathway
Wnt
SMAMDS
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
Jul 2017
→ Apr 2029
Phase 1Current
NCT08228751
2,759 pts·MDS
2017-07→2029-04·Active
2,759 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-263.1y awayPh2 Data· MDS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Active
Catalysts
Ph2 Data
2029-04-26 · 3.1y away
MDS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08228751 | Phase 1/2 | MDS | Active | 2759 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| ARG-3458 | Argenx | Preclinical | RET | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |